Latest:
Evolving Landscape of AML Therapy
Throughout this segment, the panel frames the broader conversation: AML therapy is becoming more nuanced and personalized, but clinicians must navigate increasingly complex decision-making.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Martin Barrett, PhD
Latest:
Martin Barrett on Intravenous Versus Subcutaneous Rituximab
Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Martin C. Tom, MD
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Martin Dietrich, MD, PhD
Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.
Latest:
The Role of DNA & RNA in Comprehensive Genomic Profiling
Experts discuss the critical importance of including RNA sequencing in comprehensive biomarker testing for non-small cell lung cancer (NSCLC). They highlight that while DNA-based NGS is foundational, it is insufficient for reliably detecting key gene fusions like RET and ROS1
Martin Dreyling, MD
Martin Dreyling, MD, is a full professor in the Department of Medicine at University Hospital LMU Munich.
Latest:
Dr Dreyling on the Evolving Role of BTK Inhibitors in MCL Management
Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.
Martin Forster, MD
Latest:
Dr. Forster on Next Steps With Lurbinectedin in SCLC
Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).
Martin Hutchings, MD, PhD
Latest:
Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin Lymphoma
Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.
Martin J. van den Bent, MD
Latest:
Dr. van den Bent on Temozolomide and Depatux-M in Glioblastoma
Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.
Martin Schlumberger, MD
Latest:
Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Martin van den Bent, MD, PhD
Latest:
Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer
Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.